p53 Immunohistochemical expression in Barrett's esophagus before and after endoscopic ablation by argon plasma coagulation

References

• DeMeester SR, DeMeester TR. Columnar mucosa and intestinal metaplasia of the esophagus: fifty years of controversy. Ann Surg 2000;231:303–21.
   PubMed Web of Science ®Google Scholar
• Geboes K, Van Eyken P. The diagnosis of dysplasia and malignancy in Barrett’s oesophagus. Histopathology 2000; 37:99–107.
   PubMed Web of Science ®Google Scholar
• Sampliner RE, and The Practice Parameters Committee of The American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett’s esophagus. Am J Gastroenterol 2002;97:1888–95.
   Google Scholar
• Jankowski JA, Wright NA, Meltzer SJ, Triadafilopoulos G, Geboes K, Casson AG, et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol 1999;154:965–73.
   PubMed Web of Science ®Google Scholar
• Cameron AJ. Management of Barrett’s esophagus. Mayo Clin Proc 1998;73:457–61.
   PubMed Web of Science ®Google Scholar
• Morales TG, Sampliner RE. Barrett’s esophagus: update on screening, surveillance, and treatment. Arch Intern Med 1999;159:1411–6.
   PubMedGoogle Scholar
• Triadafilopoulos G. Proton pump inhibitors for Barrett’s oesophagus. Gut 2000;46:144–6.
   PubMed Web of Science ®Google Scholar
• Haag S, Nandurkar S, Talley NJ. Regression of Barrett’s esophagus: the role of acid suppression, surgery, and ablative methods. Gastrointest Endosc 1999;50:229–40.
   Google Scholar
• Ortiz A, Martinez de Haro LF, Parrilla P, Morales G, Molina J, Bermejo J, et al. Conservative treatment versus antireflux surgery in Barrett’s oesophagus: long-term results of a prospective study. Br J Surg 1996;83:274–8.
   PubMed Web of Science ®Google Scholar
• Pereira-lima JC, Busnello JV, Saul C, Toneloto EB, Lopes CV, Rynkowski CB, et al. High power setting argon plasma coagulation for the eradication of Barrett’s esophagus. Am J Gastroenterol 2000;95:1661–8.
   Google Scholar
• Koop H. Reflux Disease and Barrett’s esophagus. Endoscopy 2000;32:101–7.
   PubMed Web of Science ®Google Scholar
• Bremner CG, DeMeester TR. Proceedings from an international conference on ablation therapy for Barrett’s mucosa. Dis Esophagus 1998;11:1–27.
   PubMedGoogle Scholar
• Wijnhoven BPL, Tilanus HW, Dinjens WNM. Molecular biology of Barrett’s adenocarcinoma. Ann Surg 2001;233: 322–37.
   PubMed Web of Science ®Google Scholar
• Krishnadath KK, Reid BJ, Wang KK. Biomarkers in Barrett esophagus. Mayo Clin Proc 2001;76:438–46.
   PubMed Web of Science ®Google Scholar
• Kubba AK, Poole NA, Watson A. Role of p53 assessment in management of Barrett’s esophagus. Dig Dis Sci 1999;44: 659–67.
   Google Scholar
• Bian Y-S, Osterheld M-C, Bosman FT, Benhattar J, Fontolliet C. p53 Gene mutation and protein accumulation during neoplastic progression in Barrett’s esophagus. Mod Pathol 2001;14: 397–403.
   Google Scholar
• Hardwick RH, Shepherd NA, Moorghen M, Newcomb PV, Alderson D. Adenocarcinoma arising in Barrett’s oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence. Gut 1994;35: 764–8.
   Google Scholar
• Krishnadath KK, Tilanus HW, Blankenstein MV, Bosman FT, Mulder AH. Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett’s oesophagus. J Pathol 1995;175: 175–80.
   Google Scholar
• Ireland AP, Clark GWB, DeMeester TR. Barrett’s esophagus: the significance of p53 in clinical practice. Ann Surg 1997;225: 17–30.
   Google Scholar
• Berenson MM, Johnson TD, Markowitz NR, Buchi KN, Samowitz WS. Restoration of squamous mucosa after ablation of Barrett’s esophageal epithelium. Gastroenterology 1993;104:1686–91.
   Google Scholar
• Wang T, Liu B, Wang L, Wang M, Jiang J. The expression and implication of proliferating cell nuclear antigen and p53 in reflux esophagitis lesions. Zhonghua Nei Ke Za Zhi 2002;41: 39–42.
   Google Scholar
• Seidal T, Balaton AJ, Battifora H. Interpretation and quantification of immunostains. Am J Surg Pathol 2001;25: 1204–7.
   PubMed Web of Science ®Google Scholar
• Jacobs TW, Prioleau JE, Stillman IE, Schnitt SJ. Loss of tumour marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst 1996;7:1054–9.
   Google Scholar
• Shi SR, Cote RJ, Taylor CR. Antigen retrieval immunohis-tochemistry: past, present, and future. J Histochem Cytochem 1997;45:327–43.
   PubMed Web of Science ®Google Scholar
• Cross SS. Grading and scoring in histopathology. Histopathology 1998;33:99–106.
   PubMed Web of Science ®Google Scholar
• Baas IO, Mulder J-WR, Offerhaus GJA, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immuno-histochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172: 5–12.
   Google Scholar
• Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry? – Revisited! J Pathol 1994;172:1–4.
   PubMed Web of Science ®Google Scholar
• Hofseth LJ, Salto S, Hussain SP, Espey MG, Miranda KM, Araki Y, et al. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. PNAS 2003;100:143–8.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick FA. Inflammation, carcinogenesis and cancer. Int Immunopharmacol 2001;1:1651–67.
   PubMed Web of Science ®Google Scholar
• Oren M. Regulation of the p53 tumour suppressor protein. J Biol Chem 1999;274:36031–4.
   PubMed Web of Science ®Google Scholar
• Biddlestone LR, Barham CP, Wilkinson SP, Barr H, Shepherd NA. The histopathology of treated Barrett’s esophagus: squamous reepithelialization after acid suppression and laser and photodynamic therapy. Am J Surg Pathol 1998;22:239–45.
   Google Scholar
• Garewal HS, Ramsey L, Sharma P, Kraus K, Sampliner R, Fass R. Biomarker studies in reversed Barrett’s esophagus. Am J Gastroenterol 1999;94:2829–33.
   PubMed Web of Science ®Google Scholar